A high polygenic risk score is associated with SSA/SSB antibody positivity and early onset in primary Sjögren's diseaseShow others and affiliations
2025 (English)In: Rheumatology, ISSN 1462-0324, E-ISSN 1462-0332, Vol. 64, no 7, p. 4341-4346Article in journal (Refereed) Published
Abstract [en]
Objectives To calculate a polygenic risk score (PRS) based on single nucleotide variants (SNVs) previously associated with primary Sj & ouml;gren's disease (SjD) with genome-wide significance and determine the genetic risk for SjD stratified by antibodies, sex and age at diagnosis. Methods Patients with SjD (n = 1065) were genotyped using Illumina OmniExpressExome chip. Control genotype data were available (n = 7742). Two PRSs were constructed, one including HLA gene variants (n = 21 SNVs), and one without HLA (n = 18 SNVs). High PRS quartile (Q4) individuals were compared with low PRS (Q1-3). Results A high PRS was associated with SSA antibody-positive SjD (OR 9.16, 95% CI 7.75-10.85, P = 3.7 x 10(-146)), and strengthened in SjD positive for both SSA/SSB antibodies (OR 13.67, 95% CI 10.88-17.32, P = 4.6 x 10(-108)). High PRS classified SSA/SSB antibody-positive SjD with very good accuracy (AUC 0.86). PRS without HLA showed a weaker association with SSA/SSB positive SjD (OR 2.09, 95% CI 1.71-2.55, P = 6.4 x 10(-13)). Antibody negative SjD displayed a PRS similar to controls. Patients in the high PRS quartile were significantly younger at diagnosis, 48.9 +/- 14.9 vs 53.4 +/- 13.4 years in the low PRS quartiles (Q1-3), P = 2.2 x 10(-6), and presented higher frequencies of ANA, SSA and SSA/SSB antibodies, P < 1 x 10(-5). Conclusion A high PRS is associated with SSA/SSB antibody positivity and early disease onset, both largely attributed to the weight of the HLA alleles. Integration of PRS with other biomarkers applied to clinical phenotypes could be a useful tool for disease risk stratification and treatment decisions.
Place, publisher, year, edition, pages
OXFORD UNIV PRESS , 2025. Vol. 64, no 7, p. 4341-4346
Keywords [en]
Sjögren's disease, polygenic risk score (PRS), single nucleotide variant (SNV), genome-wide association studies (GWAS), HLA, antinuclear antibodies, SSA, SSB
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-211060DOI: 10.1093/rheumatology/keae693ISI: 001394323500001PubMedID: 39693120Scopus ID: 2-s2.0-105010129256OAI: oai:DiVA.org:liu-211060DiVA, id: diva2:1929373
Note
Funding Agencies|Swedish Research Council [2018-05973, 2022-00637, 2021-02503]; K&A Wallenberg Foundation [KAW 2014.0272]; National Genomics Infrastructure (NGI), Science for Life Laboratory; Swedish National Infrastructure for Computing (SNIC) via Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) [sens2020501]; Swedish Rheumatism Association; King Gustaf V's 80- year Foundation; Agnes and Mac Rudberg foundation; Brunnberg foundation, Uppsala University; Norwegian Research Council; Knut and Alice Wallenberg Foundation; Swedish Heart-Lung Foundation
2025-01-202025-01-202026-04-07Bibliographically approved